The Lancet by Grosicki et al, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated patients with multiple myeloma.]]> Article Daniel E. Spratt, MD, during the virtual edition of the 2020 American Society for Radiation Oncology Annual Meeting.]]> Article JAMA Surgery, Lee et al found that the use of textured surface implants in breast reconstruction following mastectomy for breast cancer was associated with poorer disease-free survival.]]> Article Cancer Cell, demonstrated that genomic characterizations of cancer can uncover genetic alterations that may contribute to unexpected and long-lasting responses to treatment.]]> Article Article Article Article JCO Oncology Practice, Schad et al found that modifying the prostate cancer clinical pathway in an integrated oncology network to designate moderately hypofractionated external-beam radiotherapy (EBRT) as the recommended curative EBRT monotherapy in low- and intermediate-risk prostate cancer resulted in rapid uptake of the modality within 1 year.]]> Article The ASCO Post Podcast, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way in which patients with cancer choose to participate in clinical trials.]]> Podcast Joseph M. Unger, PhD, on patient interest in clinical trial enrollment: A new analysis]]> Joseph M. Unger, PhD, on patient interest in clinical trial enrollment: A new analysis]]> Video Journal of Clinical Oncology, Zamagni et al found that fluorodeoxyglucose F-18 (FDG) uptake of less than 4 on the Deauville scale in bone marrow and focal lesions on pre–maintenance therapy FDG positron-emission tomography/computed tomography scans was associated with improved survival outcomes in patients with newly diagnosed multiple myeloma.]]> Article RAS/RAF-Mutant Solid Tumors and Multiple Myeloma]]> The Lancet Oncology, Guo et al identified the phase II dose and schedule for the oral RAF/MEK inhibitor CH5126766 in patients with RAS/RAF-mutant cancers. The agent also showed antitumor activity across various malignancies.]]> Article Felasfa Wodajo, MD, Chair of Evidence-Based Medicine at MSTS and Guideline Co-Chair, discussed the recommendations.]]> Article Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III TOURMALINE-MM4 trial has shown that postinduction maintenance with ixazomib prolonged progression-free survival vs placebo in patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation.]]> Article ]]> ]]> JUNO]]> Kyprolis kdd]]> OPDIVO_HCP_Branded_Static_728x90_1506US1602315-03-01 ]]>

Treatment and Sequencing in Metastatic Castration-Resistant Prostate Cancer